Intellia Therapeutics (NTLA) AI Stock Analysis

Compare

3,477 Followers

NTLA Dividends

Top Page

Intellia Therapeutics

(NASDAQ:NTLA)

41Neutral

Intellia Therapeutics faces challenges typical for a biotech in development, such as high R&D costs leading to ongoing losses. However, the company shows promising progress in its clinical pipeline, which could lead to future revenue gains. The technical indicators suggest a bearish trend, while the valuation reflects the high-risk, high-reward nature of the industry. Positive earnings call sentiment, highlighting substantial clinical advancements, partially offsets financial weaknesses.

Positive Factors

Clinical Trial Progress

Intellia dosed the first patient in Phase 3 study of nex-z in hATTRv-PN, and enrollment in the Phase 3 trial of nex-z in ATTR-CM tracks ahead of projections, potentially accelerating the time to data.

Financial Stability

Intellia Therapeutics has a strong cash position of $707 million, providing financial stability and runway into the first half of 2027.

Innovation and Approval Potential

NTLA-2002 may be the first historic in vivo genome editing approval as HAELO BLA is on track for 2H26.

Negative Factors

Capital Market Conditions

Challenging capital markets and ongoing pipeline prioritization result in a reduction of the platform's tech value.

Competition Concerns

Brewing competition from Amvuttra (siRNA) and Attruby (pill) affects confidence in market position.

Regulatory Challenges

The price target has been adjusted to $10 from $14, based on regulatory headwinds in the gene therapy space after recent appointments at the FDA.

Intellia Therapeutics (NTLA) vs. S&P 500 (SPY)

Market Cap

$750.97M

Dividend YieldN/A

Average Volume (3M)3.51M

Price to Earnings (P/E)―

Beta (1Y)2.64

Revenue Growth-13.37%

EPS Growth2.57%

CountryUS

Employees403

SectorHealthcare

Sector Strength50

IndustryBiotechnology

Share Statistics

EPS (TTM)-1.10

Shares Outstanding103,582,730

10 Day Avg. Volume2,731,473

30 Day Avg. Volume3,507,779

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

Price to Cash Flow (P/CF)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.06

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit13.76

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$32.56

Price Target Upside300.99% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering19

Intellia Therapeutics Business Overview & Revenue Model

Company DescriptionIntellia Therapeutics (NTLA) is a leading biotechnology company specializing in the development and commercialization of CRISPR/Cas9-based gene editing therapies. The company operates in the biotech sector with a focus on creating treatments that can potentially cure a wide range of genetic diseases by precisely editing disease-causing genes. Intellia's core products are its gene-editing platforms and therapies, which are in various stages of clinical development, targeting conditions such as transthyretin amyloidosis and hereditary angioedema.

How the Company Makes MoneyIntellia Therapeutics makes money primarily through strategic collaborations, partnerships, and licensing agreements with other pharmaceutical and biotech companies. These partnerships often provide milestone payments and royalties based on the successful development and commercialization of therapies using Intellia's proprietary CRISPR/Cas9 technology. Additionally, Intellia may generate revenue from government grants and research funding to support their innovative projects. As their therapies progress through clinical trials and potentially reach the market, product sales will become a significant revenue stream for the company.

Intellia Therapeutics Financial Statement Overview

Summary

Intellia Therapeutics is in a growth phase typical for biotech firms, with high R&D expenses leading to net losses and negative cash flow. Adequate cash reserves provide some stability, but declining revenues and shareholder equity pose risks.

Income Statement

―

Intellia Therapeutics has faced a challenging financial environment, with declining revenues from $57.99 million in 2020 to $36.27 million in 2023, and ultimately to zero in 2024. The company has consistently incurred net losses, with a significant net loss of $519.02 million in 2024, indicating high operational costs and low revenue, characteristic of a biotech firm in early stages of development.

Balance Sheet

The balance sheet shows adequate cash reserves with $601.52 million in cash and equivalents. However, the debt-to-equity ratio stands at 0.24, indicating manageable leverage, but the persistent decrease in stockholders' equity from $1.05 billion in 2023 to $871.96 million in 2024 suggests a deterioration in shareholder value. The equity ratio is relatively stable, providing a moderate level of financial stability.

Cash Flow

―

The cash flow statement highlights negative free cash flow each year, with a free cash flow of -$408.07 million in 2024, driven by high operating cash outflows. The operating cash flow to net income ratio is unfavorable due to consistent losses, signaling inefficiencies in cash generation relative to expenses. This is typical for a biotech firm still in development phases.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
57.88M	36.27M	52.12M	33.05M	57.99M
	Gross Profit
57.88M	27.30M	44.55M	26.16M	-92.41M
	EBIT
-534.26M	-515.29M	-458.16M	-267.85M	-136.58M
	EBITDA
-523.98M	-506.31M	-450.59M	-260.96M	-130.27M
	Net Income Common Stockholders
-519.02M	-481.19M	-490.21M	-259.72M	-125.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
601.51M	912.22M	1.26B	1.09B	597.37M
	Total Assets
1.19B	1.30B	1.52B	1.29B	676.32M
	Total Debt
210.20M	115.35M	130.70M	74.02M	39.30M
	Net Debt
21.02M	-111.40M	-392.80M	-49.38M	-120.72M
	Total Liabilities
319.06M	250.81M	284.53M	254.22M	149.25M
	Stockholders Equity
871.96M	1.05B	1.24B	1.04B	527.07M
Cash Flow		Free Cash Flow
-408.07M	-408.07M	-391.68M	-237.79M	-53.50M
	Operating Cash Flow
-394.09M	-394.09M	-333.29M	-225.03M	-49.91M
	Investing Cash Flow
-31.35M	-31.35M	160.31M	-550.78M	-214.49M
	Financing Cash Flow
185.75M	130.32M	582.96M	736.69M	371.78M

Intellia Therapeutics Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price8.12

Price Trends

50DMA

8.29

Negative

100DMA

9.67

Negative

200DMA

14.51

Negative

Market Momentum

MACD

-0.01

Negative

RSI

50.40

Neutral

STOCH

33.37

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Neutral. The current price of 8.12 is above the 20-day moving average (MA) of 7.98, below the 50-day MA of 8.29, and below the 200-day MA of 14.51, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.40 is Neutral, neither overbought nor oversold. The STOCH value of 33.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NTLA.

Intellia Therapeutics Risk Analysis

Intellia Therapeutics disclosed 66 risk factors in its most recent earnings report. Intellia Therapeutics reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Intellia Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (52)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.17B	3.59	-42.19%	2.82%	15.05%	-0.04%
ARVN	48 Neutral	$563.49M	―	-35.41%	―	-39.92%	7.38%
VIR	48 Neutral	$777.30M	―	-44.59%	―	-73.79%	-5.24%
NRIX	47 Neutral	$735.29M	―	-64.16%	―	-30.25%	-5.92%
XNCR	45 Neutral	$601.94M	―	-33.48%	―	-25.88%	-29.16%
NTLA	41 Neutral	$750.97M	―	-57.92%	―	-13.37%	2.57%
RCKT	40 Underperform	$673.82M	―	-60.45%	―	―	6.99%

* Healthcare Sector Average

Performance Comparison

NTLA

Intellia Therapeutics

8.12

-17.30

-68.06%

XNCR

Xencor

8.33

-13.01

-60.97%

RCKT

Rocket Pharmaceuticals

6.99

-16.10

-69.73%

ARVN

Arvinas Holding Company

6.61

-24.96

-79.06%

VIR

Vir Biotechnology

5.08

-4.69

-48.00%

NRIX

Nurix Therapeutics

9.50

-4.44

-31.85%

Intellia Therapeutics Earnings Call Summary

Earnings Call Date:May 08, 2025

(Q1-2025)

% Change Since: 11.39%|

Next Earnings Date:Jul 31, 2025

Earnings Call Sentiment Positive

Intellia Therapeutics showed strong progress in its clinical pipeline with advancements in Phase 3 studies and key regulatory milestones. Financially, the company maintains a robust position despite some short-term revenue declines and restructuring costs, which are expected to bring future savings. The overall sentiment is positive, driven by significant clinical and regulatory advancements outweighing the financial challenges.

Q1-2025 Updates

Positive Updates

Progress in Phase 3 Studies

Intellia dosed the first patient in their Phase 3 study for hereditary angioedema (HAE) and for hereditary ATTR with polyneuropathy. Enrollment in the global Phase 3 HAELO study for HAE is progressing ahead of schedule, and the Phase 3 MAGNITUDE study for ATTR with cardiomyopathy is also ahead of schedule with over 90 sites actively enrolling.

Regulatory Milestones

The FDA granted Intellia the RMAT designation for nexiguran ziclumeran (nex-z) for the treatment of ATTR with cardiomyopathy, adding to prior RMAT designations for ATTR with polyneuropathy and NTLA-2002 in HAE.

Strong Financial Position

Intellia maintains a solid balance sheet with cash, cash equivalents, and marketable securities totaling approximately $707.1 million as of March 31, 2025. The company expects a year-over-year decline in GAAP operating expenses of between 5% and 10% and has sufficient funds to operate into the first half of 2027.

Positive Clinical Data

Upcoming data presentations include two-year follow-up data from NTLA-2002 at the European Academy of Allergy and Clinical Immunology Congress and longer-term data from the Phase 1 study for ATTR amyloidosis, extending the durability window out to at least three years.

Negative Updates

Decrease in Collaboration Revenue

Collaboration revenue decreased to $16.6 million during the first quarter of 2025 compared to $28.9 million during the first quarter of 2024, primarily driven by a decrease under the AvenCell License and Collaboration Agreement.

Employee and Real Estate Costs

Intellia incurred non-recurring costs related to decisions to prioritize the portfolio and reduce the real estate footprint and workforce, which affected short-term financials despite long-term cost savings.

Company Guidance

In the first quarter of 2025, Intellia achieved significant milestones, including dosing the first patients in Phase 3 studies for hereditary angioedema (HAE) and ATTR amyloidosis with polyneuropathy. Enrollment in the global Phase 3 HAELO study is progressing rapidly, with completion expected by the end of the third quarter. The Phase 3 MAGNITUDE study for ATTR with cardiomyopathy is also ahead of schedule, with over 90 active sites and cumulative enrollment expected to exceed 550 patients by year-end. Financially, Intellia reported cash, cash equivalents, and marketable securities of approximately $707.1 million as of March 31, 2025, down from $861.7 million at the end of 2024. The company maintains a strong balance sheet, with a quarterly cash use estimate of $95 million for 2025 and 2026, and expects its current cash to fund operations into the first half of 2027. Revenue for Q1 2025 was $16.6 million, with R&D expenses of $108.4 million and G&A expenses of $29 million. The company is on track to file its first BLA in 2026, with a focus on bringing one-time therapies to market efficiently.

Intellia Therapeutics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy

Intellia Therapeutics Restructures to Focus on Late-Stage Programs

Neutral

Jan 10, 2025

Intellia Therapeutics announced a strategic restructuring to focus on its late-stage programs, NTLA-2002 for HAE and nexiguran ziclumeran for ATTR amyloidosis, which includes a 27% reduction in workforce and is expected to extend the company’s cash reserves into 2027. As part of this restructuring, Laura Sepp-Lorenzino, the Chief Scientific Officer, will retire by the end of 2025, with Birgit Schultes stepping in as her successor. The company aims to advance its clinical and commercial readiness by 2026, with pivotal studies and commercialization efforts underway to address significant unmet medical needs.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.